Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland.
Department of Vaccination and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland.
Clin Exp Allergy. 2015 May;45(5):928-939. doi: 10.1111/cea.12522.
Gut microbiota and intestinal inflammation regulate the development of immune-mediated diseases, such as allergies. Fecal calprotectin is a biomarker of intestinal inflammation.
We evaluated the association of early-age fecal calprotectin levels to the later development of allergic diseases in children from farming and non-farming environments and further studied the effect of gut microbiota on the fecal calprotectin levels.
Fecal calprotectin was measured from 758 infants participating in the PASTURE study at the age of 2 months using the ELISA method. Serum-specific IgE levels were measured at 6 years of age. Data of environmental factors, doctor-diagnosed atopic dermatitis (AD) and asthma were collected by questionnaire. Multivariate logistic regression models were used for analysis. The composition of fecal microbiota was analysed in a subgroup of 120 infants with 16S rRNA pyrosequencing. The effect of Escherichia coli lipopolysaccharide (LPS) on in vitro monocyte IL-10 secretion was studied by flow cytometry.
The infants with high fecal calprotectin levels at 2 months, that is above the 90th percentile, had an increased risk of developing AD and asthma/asthmatic bronchitis by the age of 6 years (aOR 2.02 (1.06-3.85) and 2.41 (1.25-4.64), respectively). High fecal calprotectin levels correlated negatively with fecal Escherichia. LPS from E. coli stimulated production of IL-10 in monocytes.
High degree intestinal inflammation at 2 months of age, detected as high fecal calprotectin, predicted asthma and AD by the age of 6 years and was linked to low abundance of fecal Escherichia. Impaired IL-10 activation due to the lack of colonization with E. coli could explain the intestinal inflammation associated high fecal calprotectin and later risk of asthma and AD. Our results have implications for the design of probiotic treatments and suggest that early intestinal colonization has long-term health effects.
肠道微生物群和肠道炎症调节免疫介导的疾病的发展,如过敏。粪便钙卫蛋白是肠道炎症的生物标志物。
我们评估了在来自农业和非农业环境的儿童中,早期粪便钙卫蛋白水平与过敏疾病的发展之间的关系,并进一步研究了肠道微生物群对粪便钙卫蛋白水平的影响。
使用 ELISA 法测量了参加 PASTURE 研究的 758 名 2 个月大婴儿的粪便钙卫蛋白。在 6 岁时测量血清特异性 IgE 水平。通过问卷调查收集环境因素、医生诊断的特应性皮炎 (AD) 和哮喘的数据。使用多变量逻辑回归模型进行分析。对 120 名婴儿的粪便微生物群组成进行了 16S rRNA 焦磷酸测序分析。通过流式细胞术研究了大肠杆菌脂多糖 (LPS) 对体外单核细胞 IL-10 分泌的影响。
2 个月时粪便钙卫蛋白水平较高的婴儿(高于第 90 百分位),在 6 岁时患 AD 和哮喘/哮喘性支气管炎的风险增加(aOR 2.02(1.06-3.85)和 2.41(1.25-4.64))。高粪便钙卫蛋白水平与粪便大肠杆菌呈负相关。来自大肠杆菌的 LPS 刺激单核细胞产生 IL-10。
2 个月时高度肠道炎症,表现为高粪便钙卫蛋白,可预测 6 岁时的哮喘和 AD,与粪便大肠杆菌丰度低有关。由于缺乏大肠杆菌定植而导致的 IL-10 激活受损可能解释了与肠道炎症相关的高粪便钙卫蛋白和以后患哮喘和 AD 的风险。我们的研究结果对益生菌治疗的设计具有启示意义,并表明早期肠道定植具有长期健康影响。